What the PCF Patient Guide Actually Covers
The Prostate Cancer Foundation Patient Guide is a free, downloadable resource that walks you through what happens after a prostate cancer diagnosis. It covers biopsy results, Gleason scores, PSA trends, treatment options from active surveillance to radiation and surgery, side effect management, and questions you should be asking your urologist. It is not medical advice, but it is one of the cleaner overviews available without wading through marketing pages or fear-mongering forums. You can download it directly from the Prostate Cancer Foundation website at pcfa.org/patient-resources. The PDF is around 40 pages, updated periodically, and formatted for standard US letter size. It is designed to be read by patients and families, not by doctors. That distinction matters because the language assumes you have never seen a pathology report before.
Prostate Cancer Foundation Patient Guide
I pulled the current version down last year when my father went in for his biopsy results. The guide itself is fine, but here is the thing nobody tells you: the downloadable PDF is static. If PCF updates the treatment algorithms because new clinical data drops, you are still sitting on the old version unless you re-download. I noticed this when my father was comparing the guide to the NCCN guidelines his oncologist was using. There was a gap on the sentence about ADT duration for intermediate-risk cases. The guide listed a general range; the NCCN had specifics that had shifted in the 2024 update. The workaround was straightforward. I bookmarked the PCF patient resources page and checked it every few months. Two minutes, honestly. But I wasted a full appointment discussing outdated information before I caught it. Another practical note about the guide that most people miss: the treatment decision flowcharts inside it are simplified to the point of being somewhat misleading if you have a complex case. The flowchart assumes a linear path from diagnosis to treatment selection. Real life rarely works that way. I saw this firsthand when a reader in the PCF community forum posted about his case. He had a Gleason 3+4=7, PSA of 8.2, and a family history of BRCA2 mutation. The guide's flowchart would have steered him toward surgery as the default intermediate-risk path. His actual discussion with his multidisciplinary team ended up favoring radiation plus short-course hormone therapy because of the genetic factor. The guide does not cover genomic testing or hereditary risk profiles in any depth. It is a starting point, not a map for the full terrain. The sections I found most useful were the ones explaining PSA kinetics and the glossary of terms. PSA velocity, PSA doubling time, percent free PSA — these are concepts that urologists use constantly in conversation but rarely explain in plain language during a clinic visit. The guide breaks them down without condescension, which is rare. The appendix with sample questions for your doctor was also practical. I printed it out and brought it to my father's consultation. We went through twelve questions he had written down, and the physician actually had time to answer eight of them before the next patient was called in. That is about average for a 15-minute follow-up appointment.
There are limitations worth being blunt about. The guide does not address quality of life after treatment in the detail some patients need. Sexual function, urinary incontinence, bowel changes — these get a paragraph or two each, usually in the treatment outcome sections, but not enough for someone actually living through the recovery. You will need supplementary resources for that. PCF does have separate fact sheets on sexual health and urinary side effects, but they are scattered across the website and not linked prominently from the main guide. Also, the guide does not cover clinical trials or how to find them. If you are under 65 and have localized disease, that gap could be significant. The other downside is that the guide assumes you have access to a urologist and an oncology team. It does not address what happens if you are uninsured or living in an area with limited specialist access. The patient navigation resources mentioned in passing in the guide are real but vary wildly by state and insurance type. I wish PCF had made that clearer. A brief section on how to access financial assistance programs or patient navigation services would have saved my father several weeks of going back and forth with billing departments. Overall, the Prostate Cancer Foundation Patient Guide is one of the better free resources available for newly diagnosed patients. It is accurate, well-organized, and written by clinicians who understand what a patient needs to hear first. But treat it as an introduction, not a complete reference. Cross-reference the treatment sections with the NCCN Guidelines for Patients, which are more detailed and updated more frequently. And always, always re-download the PDF if more than six months have passed since your last check-in with the PCF website. Medicine moves fast enough that even a good patient guide can become stale without much effort.
Get the Full Details
